Company news

Intensity Therapeutics, Inc. news in 2026

Intensity Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

November 5, 2026

Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026

October 30, 2026

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting

October 23, 2026

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO...

October 23, 2026

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

August 4, 2026

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

July 15, 2026

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

April 15, 2026

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

March 26, 2026

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

March 23, 2026

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

March 11, 2026

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

March 5, 2026

Intensity Therapeutics Announces Reverse Stock Split

February 13, 2026

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

January 13, 2026

Calls in 2026